Company Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-23 pm EDT 5-day change 1st Jan Change
29.35 USD -2.78% Intraday chart for Harmony Biosciences Holdings, Inc. +0.14% -9.13%

Business Summary

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Number of employees: 246

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
438 100.0 % 582 100.0 % +32.93%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
438 100.0 % 582 100.0 % +32.93%

Managers

Managers TitleAgeSince
Chief Executive Officer 66 17-10-31
Director of Finance/CFO 54 21-03-28
Chief Tech/Sci/R&D Officer 53 -
Chief Tech/Sci/R&D Officer 62 -
Compliance Officer - -
Investor Relations Contact - 22-02-28
Corporate Officer/Principal - -
Human Resources Officer - -
Corporate Officer/Principal - -
General Counsel - 20-12-31

Members of the board

Members of the board TitleAgeSince
Founder 56 17-07-24
Director/Board Member 59 20-11-10
Director/Board Member 64 17-08-31
Director/Board Member 60 17-08-31
Director/Board Member 62 20-07-31
Director/Board Member 53 17-08-31
Director/Board Member 53 Nov. 04
Director/Board Member 59 16-12-31
Chief Executive Officer 66 17-10-31
Director/Board Member 58 21-11-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 56,791,861 33,312,898 ( 58.66 %) 0 58.66 %

Shareholders

NameEquities%Valuation
Valor Management LLC
19.76 %
11,218,033 19.76 % 325 M $
Marshman Fund Trust Ii
18.76 %
10,651,120 18.76 % 308 M $
BlackRock Advisors LLC
9.747 %
5,533,390 9.747 % 160 M $
Fidelity Management & Research Co. LLC
9.258 %
5,255,518 9.258 % 152 M $
Vanguard Fiduciary Trust Co.
6.391 %
3,628,225 6.391 % 105 M $
Vivo Capital LLC
4.591 %
2,606,247 4.591 % 75 M $
Pacer Advisors, Inc.
4.395 %
2,494,914 4.395 % 72 M $
HBM Partners AG (Investment Management)
3.784 %
2,147,943 3.784 % 62 M $
1,295,544 2.282 % 37 M $
venBio Partners LLC
1.824 %
1,035,396 1.824 % 30 M $

Company contact information

Harmony Biosciences Holdings, Inc.

630 West Germantown Pike Suite 215

19462, Plymouth Meeting

+

http://www.harmonybiosciences.com
address Harmony Biosciences Holdings, Inc.(HRMY)
  1. Stock Market
  2. Equities
  3. HRMY Stock
  4. Company Harmony Biosciences Holdings, Inc.